Marasca Roberto, Maffei Rossana, Morselli Monica, Zucchini Patrizia, Castelli Ilaria, Martinelli Silvia, Fontana Marcella, Ravanetti Sara, Curotti Monica, Leonardi Giovanna, Cagossi Katia, Partesotti Giovanni, Torelli Giuseppe
Department of Oncology and Hematology, University of Modena and Reggio Emilia, Via Del Pozzo 71, 41100 Modena, Italy.
J Mol Diagn. 2005 Nov;7(5):566-74. doi: 10.1016/S1525-1578(10)60589-2.
The immunoglobulin (Ig) mutational status in B-cell chronic lymphocytic leukemia (CLL) distinguishes two subsets of patients with different prognosis. Ig status detection is commonly performed with a panel of V(H) family-specific primers. Although this method detects clonal VDJ rearrangement in virtually all cases, it is technically cumbersome and therefore not widely used clinically. Here, we describe a simple and rapid method to establish the mutational status of IgV(H) in CLL. The method is based on a consensus V(H) FR2 primer, used in both polymerase chain reaction (PCR) and sequencing reactions. Overall, monoclonal B-cell populations were detected in 163 of 189 CLL patients (86%). The prognostic value of IgV(H) mutational status was then evaluated by analyzing survival in 146 CLL cases using different V(H) homology cutoffs. CLL prognostic groups were best separated by the classical 98% cutoff: median survival was 127 and 206 months in unmutated and mutated CLL cases, respectively (P = 0.0023). V(H) FR2 consensus and V(H) family PCR were compared in 41 cases, correctly assigning all cases by both methods. Therefore, we suggest a sequential strategy to detect immunoglobulin mutational status in CLL patients by first using the approach described in this study followed by alternative V(H) family-specific PCRs for negative cases.
B 细胞慢性淋巴细胞白血病(CLL)中的免疫球蛋白(Ig)突变状态可区分出预后不同的两个患者亚组。Ig 状态检测通常使用一组 V(H)家族特异性引物进行。尽管这种方法在几乎所有病例中都能检测到克隆性 VDJ 重排,但技术操作繁琐,因此在临床上未广泛应用。在此,我们描述一种简单快速的方法来确定 CLL 中 IgV(H)的突变状态。该方法基于一种用于聚合酶链反应(PCR)和测序反应的共有 V(H) FR2 引物。总体而言,189 例 CLL 患者中有 163 例(86%)检测到单克隆 B 细胞群体。然后通过分析 146 例 CLL 病例在不同 V(H)同源性阈值下的生存情况来评估 IgV(H)突变状态的预后价值。CLL 预后组通过经典的 98%阈值能得到最佳区分:未突变和突变的 CLL 病例的中位生存期分别为 127 个月和 206 个月(P = 0.0023)。在 41 例病例中比较了 V(H) FR2 共有引物和 V(H)家族 PCR,两种方法对所有病例的分类均正确。因此,我们建议采用一种序贯策略来检测 CLL 患者的免疫球蛋白突变状态,即首先使用本研究中描述的方法,然后对阴性病例采用替代的 V(H)家族特异性 PCR。